Advances in the Treatment of Mucoepidermoid Carcinoma

Sama, Srikar; Komiya, Takefumi; Guddati, Achuta Kumar

doi:10.14740/wjon1412

Cited by 24 publications

(19 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although EGFR overexpression on IHC may not be the case in all patients harboring the CRTC1-MAML2 fusion, responses to EGFR inhibitors, such as erlotinib, gefitinib, or cetuximab, have been reported sporadically, making such approaches an attractive option for patients with MEC [40]. However, approaches that used different TKIs, including lapatinib, nintedanib or sorafenib, have failed to demonstrate consistent antitumor activity in patients with MEC [59].…”

Section: Mucoepidermoid Carcinomamentioning

confidence: 99%

New Systemic Therapies in Salivary Gland Cancer

Vathiotis

Johnson

Argiris

2023

Critical Issues in Head and Neck Oncology

View full text Add to dashboard Cite

Salivary gland cancer (SGC) encompasses a group of rare malignancies with distinct molecular, histologic, and clinical characteristics. Rarity as well as evolving disease heterogeneity have made treatments particularly challenging, with classic chemotherapy agents showing at best moderate antitumor efficacy in patients with recurrent or metastatic SGC. Recent advances in genomic profiling have provided relevant targets for different subtypes of SGC, enabling tailoring of therapeutic approaches. Despite the lack of predictive biomarkers, treatment with immune checkpoint inhibitors also appears to benefit a subgroup of patients. This chapter aims to give a comprehensive overview of novel approaches to systemic therapy for patients with recurrent or metastatic SGC.

show abstract

Section: Mucoepidermoid Carcinomamentioning

confidence: 99%

New Systemic Therapies in Salivary Gland Cancer

Vathiotis

Johnson

Argiris

2023

Critical Issues in Head and Neck Oncology

View full text Add to dashboard Cite

show abstract

“…For grade III or IV malignant tumors, one can choose to undergo postoperative chemotherapy along with radiotherapy or participate in clinical trials for innovative treatments. [62] In the nonneoplastic lesions, the treatment is varied depending on each individual pathology. Thus, it can be an etiological 1 (for example smoking cessation), with local or systemic administration of corticosteroids, antibiotic therapy or antiviral medication, or lithotripsy in cases of sialolithiasis.…”

Section: Diagnosismentioning

confidence: 99%

A retrospective study of nonneoplastic and neoplastic disorders of the salivary glands

Vamesu,

Ursica,

Gurita

et al. 2023

Medicine

View full text Add to dashboard Cite

The spectrum of major and minor salivary gland disorders varies widely. Epidemiological data on some injury categories are rare and often not up-to-date. This study aims to analyze epidemiological data using clinical, paraclinical, and histopathological parameters. Study was carried out for 5 years on the nonneoplastic and tumoral pathology of the salivary glands. Data were statistically analyzed using the appropriate parameters. Data analysis according to the biological behavior of the lesions revealed great heterogeneity. Statistically significant correlations were observed between the type of injury, age (P = .002) and gender (0.033). The environment of origin of the patients as well as the comorbidities reflected in most cases the nature of the process. Associations were also observed between the biological behavior of the lesions and the hemicranial topography (P = .019), the type of salivary gland (P = .024), and the surgical technique used (P < .001). Most cases were identified in the major salivary glands, often in the parotid. The most common diseases are represented by nonspecific chronic sialadenitis (nonneoplastic lesion), pleomorphic adenoma and Warthin tumor (benign tumors), mucoepidermoid carcinoma (malignant tumor), and squamous carcinoma (secondary tumor). They presented axial diameters between 2 to 95 mm. The most used curative technique was subtotal excision with facial nerve preservation. In conclusion, the study highlighted the main epidemiological aspects of salivary gland disorders. Some data agree with the specialty literature, and particular aspects are also observed. Therefore, this research is useful both in the medical and research fields.

show abstract

“…Mucoepidermoid carcinoma (MEC) accounts for 5–15% of all salivary gland malignancies but less than 1% of all head and neck cancers [ 1 , 2 ]. MEC is a heterogeneous tumor composed of various proportions of mucin-secreting, epidermoid, and intermediate cells.…”

Section: Introductionmentioning

confidence: 99%

Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens

Yamanaka

Suzuki²,

Ito³

et al. 2023

IJMS

View full text Add to dashboard Cite

Patients with advanced/recurrent mucoepidermoid carcinoma (MEC) have a poor prognosis. This study aimed to establish and characterize human mucoepidermoid carcinoma cell lines from the initial surgical specimen and biopsy specimen upon recurrence from the same patient to provide a resource for MEC research. MEC specimens from the initial surgical procedure and biopsy upon recurrence were used to establish cell lines. The established cell lines were cytogenetically characterized using multi-color fluorescence in situ hybridization and detection, and the sequence of the CRTC1-MAML2 chimeric gene was determined. Furthermore, the susceptibility of head and neck mucoepidermoid carcinoma to standard treatment drugs such as cisplatin, 5-fluorouracil, and cetuximab was investigated. We successfully established unique MEC cell lines, AMU-MEC1, from an initial surgical specimen and AMU-MEC1-R1 and AMU-MEC1-R2 from the recurrent biopsy specimen in the same patient. These cell lines exhibited epithelial morphology and developed in vitro-like cobblestones. They shared eight chromosomal abnormalities, including der(19)ins(19;11)(p13;?), which resulted in a chimeric CRTC1-MAML2 gene, indicating the same origin of the cell lines. The susceptibility of all cell lines to cisplatin and 5-fluorouracil was low. Interestingly, EGFR dependency for cell growth decreased in AMU-MEC-R1 and AMU-MEC-R2 but was retained in AMU-MEC1. These cytogenetic and biochemical findings suggest that the established cell lines can be used to investigate the disease progression mechanisms and develop novel therapeutics for MEC.

show abstract

Advances in the Treatment of Mucoepidermoid Carcinoma

Cited by 24 publications

References 60 publications

New Systemic Therapies in Salivary Gland Cancer

New Systemic Therapies in Salivary Gland Cancer

A retrospective study of nonneoplastic and neoplastic disorders of the salivary glands

Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens

Contact Info

Product

Resources

About